Diversity alone isn't a reason to invest in a stock, but companies dominated by alpha males and old white guys may end up costing shareholders.» Read More
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.
Joseph Keating, chief investment officer at First American Asset Management, told CNBC’s “Squawk on the Street” that dividend stocks are a good bet in retirement.
In TV's worst spring in recent memory, an alarming number of Americans drifted away from television the past two months: More than 2.5 million fewer people were watching ABC, CBS, NBC and Fox than at the same time last year, statistics show.
Two studies and an editorial in the journal of the American Medical Association are raising even more questions about the safety of drug-coated stents and could further hurt already-declining sales.
Michael Krensavage, pharmaceutical analyst at Raymond James, told CNBC’s “Morning Call” that strong revenue and earnings growth will reward investors in the pharmaceutical sector.
U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen and Johnson & Johnson , according to an agency document released on Tuesday.
Johnson & Johnson on Monday said it will meet a prior 2007 earnings forecast despite the failure of a highly-anticipated heart device in a key study.
Searching for nuggets of wisdom from the Oracle of Omaha.
Earnings blowouts and encouraging drug trials were some of the catalysts behind Thursday's most actively traded stocks.
Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.
Abbott Laboratories said on Wednesday its first-quarter earnings fell 19% as charges related to acquisitions and cost-cutting offset sharply higher sales of its prescription drugs and medical devices.
Cramer's got the call on Bank of America, Jones Soda, AIG and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The Dow closed within striking distance of a new record following another batch of strong earnings reports. "I think this market is acting great," said Todd Leone head of listed trading at Cowen & Company. "We've had a tremendous rally and we’re still making a number of new highs. It's really acting well."
Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs have come under increasing scrutiny over safety.
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
Stocks are set to open higher, reversing an early negative trend, after consumer inflation data showed muted increases in core inflation. However, the CPI rose at a 0.6% rate when including food and energy, its highest rise since last April. Housing starts rose 0.8%, beating analysts expectatons but below February's increase.
Boston Scientific said on Monday it had resolved deficiencies that U.S. regulators had found at a plant that manufactures heart rhythm devices, sending its shares up nearly 7%.
The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.
Nobody stays best of breed forever. And no matter how you feel about a company's reputation, only the fundamentals matter at end of day. For that reason, you should never hesitate to clear a poor performer from your portfolio - no matter how much of a blue chip you think it is.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.